The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Department of Anesthesiology, Zigong First People's Hospital, Zigong Academy of Medical Sciences, Zigong, China.
Mitochondrion. 2024 Nov;79:101974. doi: 10.1016/j.mito.2024.101974. Epub 2024 Oct 24.
Ischemia-reperfusion injury (IRI) is a major cause of mortality and morbidity. Current treatments for IRI have limited efficacy and novel therapeutic strategies are needed. Mitochondrial dysfunction not only initiates IRI but also plays a significant role in ferroptosis pathogenesis. Recent studies have highlighted that targeting mitochondrial pathways is a promising therapeutic approach for ferroptosis-induced IRI. The association between ferroptosis and IRI has been reviewed many times, but our review provides the first comprehensive overview with a focus on recent mitochondrial research. First, we present the role of mitochondria in ferroptosis. Then, we summarize the evidence on mitochondrial manipulation of ferroptosis in IRI and review recent therapeutic strategies aimed at targeting mitochondria-related ferroptosis to mitigate IRI. We hope our review will provide new ideas for the treatment of IRI and accelerate the transition from bench to bedside.
缺血再灌注损伤(IRI)是导致死亡率和发病率的主要原因。目前治疗 IRI 的方法疗效有限,需要新的治疗策略。线粒体功能障碍不仅引发 IRI,而且在铁死亡发病机制中也起着重要作用。最近的研究强调,靶向线粒体途径是治疗铁死亡诱导的 IRI 的一种很有前途的方法。铁死亡和 IRI 之间的关联已经被多次综述,但我们的综述首次提供了一个全面的概述,重点是最近的线粒体研究。首先,我们介绍了线粒体在铁死亡中的作用。然后,我们总结了线粒体在 IRI 中铁死亡中的作用的证据,并回顾了最近旨在靶向与线粒体相关的铁死亡以减轻 IRI 的治疗策略。我们希望我们的综述能为 IRI 的治疗提供新的思路,并加速从基础研究到临床应用的转化。